Drug Approval | January 02, 2025
Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
LG Chem will receive totaling up to $95.5 million for the China rights
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Subscribe To Our Newsletter & Stay Updated
